[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review

March 2021 | 71 pages | ID: R8CF600A833EN
GlobalData

US$ 125.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Regeneron Pharmaceuticals Inc (REGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Regeneron Pharmaceuticals Inc (Regeneron) discovers, develops, manufactures, and markets medicines for the treatment of serious medical conditions. Its marketed and pipeline products are focused on helping patients suffering with cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi and other related technologies. The company operates manufacturing facilities in Rensselaer, New York and Limerick, Ireland. It also works in collaboration with strategic partners to develop, manufacture and commercialize its products. It sells its products to specialty pharmacies and distributors. The company and its subsidiaries operate in the US, the Netherlands, Bermuda, Ireland, Spain and the UK. Regeneron is headquartered in Tarrytown, New York, the US.

Regeneron Pharmaceuticals Inc Key Recent Developments

Feb 24,2021: Regenron’s antibodies demonstrate promise against MERS-CoV in NIH trial
Feb 05,2021: Regeneron reports fourth quarter and full year 2020 financial and operating results
Nov 05,2020: Regeneron reports third quarter 2020 financial and operating results
Oct 05,2020: Allele Biotechnology and Pharmaceuticals files two lawsuits for patent infringement for the unauthorized use of mNeonGreen in development and testing of covid vaccines and therapeutics
Oct 05,2020: Pfizer, BioNTech, and Regeneron hit with Patent lawsuits over COVID-19 drugs and vaccines

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Regeneron Pharmaceuticals Inc - Key Facts
Regeneron Pharmaceuticals Inc - Key Employees
Regeneron Pharmaceuticals Inc - Key Employee Biographies
Regeneron Pharmaceuticals Inc - Major Products and Services
Regeneron Pharmaceuticals Inc - History
Regeneron Pharmaceuticals Inc - Company Statement
Regeneron Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Regeneron Pharmaceuticals Inc - Business Description
Product Category: Arcalyst
Overview
Performance
Product Category: Eylea
Overview
Performance
Product Category: Libtayo
Overview
Performance
Product Category: Other revenue
Performance
Product Category: Praluent
Overview
Performance
Product Category: Regen-COV
Overview
Performance
Product Category: Sanofi and Bayer collaboration revenue
Performance
R&D Overview
Regeneron Pharmaceuticals Inc - Corporate Strategy
Regeneron Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Regeneron Pharmaceuticals Inc - Strengths
Regeneron Pharmaceuticals Inc - Weaknesses
Regeneron Pharmaceuticals Inc - Opportunities
Regeneron Pharmaceuticals Inc - Threats
Regeneron Pharmaceuticals Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Regeneron Pharmaceuticals Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 24, 2021: Regenron’s antibodies demonstrate promise against MERS-CoV in NIH trial
Feb 05, 2021: Regeneron reports fourth quarter and full year 2020 financial and operating results
Nov 05, 2020: Regeneron reports third quarter 2020 financial and operating results
Oct 05, 2020: Allele Biotechnology and Pharmaceuticals files two lawsuits for patent infringement for the unauthorized use of mNeonGreen in development and testing of covid vaccines and therapeutics
Oct 05, 2020: Pfizer, BioNTech, and Regeneron hit with Patent lawsuits over COVID-19 drugs and vaccines
Sep 15, 2020: Regeneron and University of Lausanne publish Newomics M3 Emitters
Sep 05, 2020: Kaskela Law announces investigation of Regeneron Pharmaceuticals (Regn) and encourages long-term Regn stockholders to contact the firm
Aug 20, 2020: Roche teams up with Regeneron on Covid-19 therapy
Aug 05, 2020: Regeneron reports second quarter 2020 financial and operating results
Jul 07, 2020: Regeneron Pharmaceuticals: Entry into a material definitive agreement

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Regeneron Pharmaceuticals Inc, Key Facts
Regeneron Pharmaceuticals Inc, Key Employees
Regeneron Pharmaceuticals Inc, Key Employee Biographies
Regeneron Pharmaceuticals Inc, Major Products and Services
Regeneron Pharmaceuticals Inc, History
Regeneron Pharmaceuticals Inc, Other Locations
Regeneron Pharmaceuticals Inc, Subsidiaries
Regeneron Pharmaceuticals Inc, Key Competitors
Regeneron Pharmaceuticals Inc, Ratios based on current share price
Regeneron Pharmaceuticals Inc, Annual Ratios
Regeneron Pharmaceuticals Inc, Annual Ratios (Cont...1)
Regeneron Pharmaceuticals Inc, Annual Ratios (Cont...2)
Regeneron Pharmaceuticals Inc, Interim Ratios
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Regeneron Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Regeneron Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Regeneron Pharmaceuticals Inc, Ratio Charts
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Regeneron Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021


More Publications